New registry tracks rezdiffra safety in pregnant NASH patients
NCT ID NCT07541469
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study is a registry that collects information on the safety of Rezdiffra (resmetirom) in women with NASH who took the drug during pregnancy or while breastfeeding, and their infants up to 12 months old. It does not give any treatment or change care—it simply observes and records pregnancy outcomes, birth defects, and baby growth and development. The goal is to better understand any risks, helping doctors and patients make informed decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Madrigal Pharmaceuticals
RECRUITINGWest Conshohocken, Pennsylvania, 19428, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.